The Clinical Trial of FK 506 As Primary and Rescue Immunosuppression in Pediatric Cardiac Transplantation
Overview
Affiliations
Tacrolimus: in heart transplant recipients.
McCormack P, Keating G Drugs. 2006; 66(17):2269-79.
PMID: 17137409 DOI: 10.2165/00003495-200666170-00010.
Two-year experience with FK 506 in pediatric patients.
Tzakis A, Reyes J, Todo S, Nour B, Shapiro R, Jordan M Transplant Proc. 1993; 25(1 Pt 1):619-21.
PMID: 7679822 PMC: 2991121.
Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506.
Armitage J, Fricker F, Kurland G, Hardesty R, Michaels M, Morita S J Thorac Cardiovasc Surg. 1993; 105(2):337-45; discussion 346.
PMID: 7679172 PMC: 3227140.
A risk-benefit assessment of tacrolimus in transplantation.
Winkler M, Christians U Drug Saf. 1995; 12(5):348-57.
PMID: 7545405 DOI: 10.2165/00002018-199512050-00006.
A prospective randomized trial of FK506-based immunosuppression after renal transplantation.
Shapiro R, Jordan M, Scantlebury V, Vivas C, Fung J, McCauley J Transplantation. 1995; 59(4):485-90.
PMID: 7533343 PMC: 2952527. DOI: 10.1097/00007890-199559040-00007.